Pieris Pharmaceuticals, Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Note 7 - 2019 Equity Incentive Plan 3 (Tables)

Note 7 - 2019 Equity Incentive Plan 3 (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		Common				Weighted				Weighted
		Shares				Average				Average
		Underlying				Exercise				Remaining
		Stock				Price per				Contractual
		Options				Share				Life (Years)
Outstanding at December 31, 2023			1,581,041			$	2.72				7.3
Granted			568,097				2.33
Exercised			—
Forfeited / Cancelled			—
Outstanding at September 30, 2024			2,149,138			$	2.62				7.4

Exercisable at September 30, 2024			1,287,990			$	2.61				6.2

		Common				Weighted				Weighted
		Shares				Average				Average
		Underlying				Exercise				Remaining
		Stock				Price per				Contractual
		Options				Share				Life (Years)
Outstanding at January 1, 2023			1,024,628			$	2.53				7.1
Granted			608,388				3.03
Exercised			—
Forfeited / Cancelled			(51,975	)			2.64
Outstanding at December 31, 2023			1,581,041			$	2.72				7.3

Exercisable at December 31, 2023			1,009,011			$	2.56				6.5

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Expected volatility			80.14%	-	81.01	%
Risk-free interest			4.05%	-	4.08	%
Expected term (years)			5.4	-	6.0
Expected dividend yield					—